Adaptive Biotechnologies (ADPT) Receivables - Other (2018 - 2026)

Adaptive Biotechnologies has disclosed Receivables - Other across 9 years of filings, most recently posting $1.8 million for Q2 2026.

• In Q2 2026, Receivables - Other rose 38.46% year-over-year to $1.8 million; the TTM figure through Jun 2026 stood at $1.8 million (up 38.46% YoY), while the FY2025 annual figure was $1.5 million, up 15.38% from the prior year.
• Receivables - Other came in at $1.8 million for Q2 2026 at Adaptive Biotechnologies, up from $1.6 million in the prior quarter.
• In the past five years, Receivables - Other ranged from a high of $1.8 million in Q2 2026 to a low of $800000.0 in Q2 2022.
• Average Receivables - Other over 5 years is $1.2 million, with a median of $1.2 million recorded in 2022.
• Year-over-year, Receivables - Other slumped 65.22% in 2022 and soared 38.46% in 2026.
• Over 5 years, Receivables - Other stood at $800000.0 in 2022, then gained by 25.0% to $1.0 million in 2023, then climbed by 30.0% to $1.3 million in 2024, then grew by 15.38% to $1.5 million in 2025, then grew by 20.0% to $1.8 million in 2026.
• Per Business Quant data, the three most recent Receivables - Other figures were $1.8 million in Q2 2026, $1.6 million in Q1 2026, and $1.5 million in Q4 2025.